Riskpilot← Back to searchSign inGet full accessLIPLASOME PHARMA ApS
APSActiveCVR 29428514Tabletvej 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20062 employees
Revenue 2025
DKK -28K
-47% vs 2024
EBITDA margin
100.0%
+47% vs 2024
Equity ratio
99.5%
Financial strength
Net profit 2025
DKK 62K
+272% vs 2024
| Revenue | DKK -28K | -47% |
| EBITDA | DKK -28K | +47% |
| Net profit | DKK 62K | +272% |
| Total assets | DKK 2,4M | +3% |
| Equity | DKK 2,4M | +3% |
| Employees | 2 | — |
Legal name
LIPLASOME PHARMA ApS
CVR number
29428514
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8. februar 2006
Share capital
DKK 92.402
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at videreudvikle og kom¬mer¬cialisere selskabets delivery tek-nologi primært indenfor cancerbehandling.
Address
Tabletvej 1
Phone
+4549288888
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -850 | -1.161 | -1.519 | -1.723 | -328 | -65 | -61 | -81 | -133 | 108 | 2.202 | -29 | -53 | -28 |
| Staff expenses | -1.827 | -1.534 | -1.405 | -1.469 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -2.677 | -2.695 | -2.924 | -3.192 | -329 | -65 | -61 | -81 | -133 | 108 | 2.202 | -29 | -53 | -28 |
| Depreciation & amort. | 33 | -240 | -264 | -264 | -33 | -0 | -0 | -38.245 | -51 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.710 | -2.935 | -3.188 | -3.456 | -362 | -65 | -61 | -38.326 | -184 | 108 | 2.202 | -29 | -53 | -28 |
| Net financials | -292 | -3 | -21 | -17 | -34 | -6 | -8 | -7 | -16 | -10 | -6 | 3 | 7 | 90 |
| Profit before tax | -3.002 | 2.644 | -1.593 | -3.473 | -396 | -71 | -69 | -38.333 | -200 | 98 | 2.196 | -26 | -46 | 62 |
| Tax | -0 | 2.791 | 808 | -982 | -87 | -16 | -15 | -4.782 | -44 | -0 | -0 | -6 | -10 | -0 |
| Net profit | -3.002 | -147 | -2.401 | -2.491 | -309 | -55 | -54 | -33.551 | -156 | 98 | 2.196 | -20 | -36 | 62 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 20.587 | 35.121 | 34.387 | 40.739 | 38.190 | 38.473 | 38.273 | 571 | 1.524 | 186 | 2.383 | 2.363 | 2.330 | 2.389 |
| Equity | 19.741 | 34.195 | 31.794 | 34.202 | 33.893 | 33.838 | 33.784 | 233 | 77 | 175 | 2.371 | 2.351 | 2.315 | 2.377 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 846 | 926 | 1.322 | 2.879 | 207 | 288 | 157 | 338 | 1.447 | 11 | 12 | 12 | 15 | 12 |
| Total debt | 846 | 926 | 1.322 | 2.879 | 207 | 288 | 157 | 338 | 1.447 | 11 | 12 | 12 | 15 | 12 |
EBITDA margin
-2800000.0%
This company
15.8%
Market median
-17721619% vs market
20122025
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20122025
Return on equity
2.6%
This company
18.4%
Market median
-86% vs market
20122025
Net profit margin
6200000.0%
This company
8.1%
Market median
+76543110% vs market
20122025
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20122025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HH Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2011 | — | — | |
OL | Board of Directors | 2006 | — | — |
| Board of Directors | 2012 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2006 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2008 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BAGGER-SØRENSEN & CO. A/S | Company | 90.0% | 90.0% | 2022 |
VECATA INVEST ApS | Company | 90.0% | 90.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
S. Bagger-Sørensen Invest ApS
LIPLASOME PHARMA ApS Board members of LIPLASOME PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans-Henrik Horsted Eriksen | Chief Executive Officer | 0 companies |
| Claus Bagger-Sørensen | Board of Directors | 0 companies |
| Torben Vilsgaard | Board of Directors | 0 companies |
| Ole Lund | Board of Directors | 0 companies |
| Duncan Moore | Board of Directors | 0 companies |
| Sanjay Kumar Sehgal | Board of Directors | 0 companies |
| Holger Bagger-Sørensen | Chairman | 0 companies |
| John Riis Mortensen | Chairman | 0 companies |
| Torben Brøgger-Mikkelsen | Board of Directors | 0 companies |
| Steen Bagger-Sørensen | Board of Directors | 0 companies |
| Peter Buhl | Board of Directors | 0 companies |